KRAS and non-small cell lung carcinoma: To assess the potential therapeutic application of targeting METTL3 in KRAS-mutant NSCLC cells, we employed a small molecule, STM2457, which potently and selectively inhibited METTL3 enzymatic activity in a recent study (46).